Volume 10, Number 5—May 2004
Research
Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients
Jann-Tay Wang*, Wang-Huei Sheng*, Chi-Tai Fang*, Yee-Chun Chen*, Jiun-Ling Wang*, Chong-Jen Yu*, Shan-Chwen Chang*
, and Pan-Chyr Yang*
, and Pan-Chyr Yang*
Table 3
Data on most severe abnormal laboratory parameters of 76 SARS patients during their disease coursea
| Laboratory parameters (no. of patients, %) | Mean ± SD of most severe data (unit) | Duration from disease onset to most severe data noted |
|---|---|---|
| Leukopenia (40, 52.6) |
2.5 ± 0.7 (x 109/L) |
7.5 ± 2.4 days |
| Lymphopenia (72, 94.7) |
0.6 ± 0.3 (X 109/L) |
7.0 ± 2.5 days |
| Thrombocytopenia (61, 80.3) |
102.3 ± 31.3 (X 109/L) |
6.9 ± 2.0 days |
| Elevated AST (66, 86.9) |
142.0 ± 323.6 (U/L) |
10.3 ± 4.6 days |
| Elevated ALT (59, 77.6) |
103.7 ± 132.2 (U/L) |
13.3 ± 5.0 days |
| Elevated LDH (73, 96.1) |
1323.8 ± 1487.2 (U/L) |
10.8 ± 3.9 days |
| Elevated CK (34, 44.7) |
12165.7 ± 58226.9 (U/L) |
7.8 ± 4.2 days |
| Elevated CRP (71, 93.4) | 7.1 ± 4.0 (mg/dL) | 8.5 ± 3.0 days |
aSARS, severe acute respiratory syndrome; SD, standard deviation.
Page created: February 22, 2011
Page updated: February 22, 2011
Page reviewed: February 22, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.